Improvement in poor graft function after allogeneic hematopoietic stem cell transplantation upon administration of mesenchymal stem cells from third-party donors: A pilot prospective study

Cell Transplantation

Volumn 23, Issue 9, 2014, Pages 1087-1098

  Liu, Xiaodan ^a,b   Wu, Meiqing ^a   Peng, Yanwen ^c   Chen, Xiaoyong ^c   Sun, Jing ^a   Huang, Fen ^a   Fan, Zhiping ^a   Zhou, Hongsheng ^a   Wu, Xiuli ^a   Yu, Guopan ^a   Zhang, Xian ^a   Li, Yonghua ^d   Xiao, Yang ^d   Song, Chaoyang ^e   Peng Xiang, Andy ^c   Liu, Qifa ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b QINGDAO UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^e SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Allogeneic hematopoietic stem cell transplantation (allo HSCT); Mesenchymal stem cells (MSCs); Poor graft function (PGF); Third party donors

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; THYMOCYTE ANTIBODY; VIRUS DNA;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; BONE MARROW; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; DELAYED GRAFT FUNCTION; DONOR; DONOR LYMPHOCYTE INFUSION; EPSTEIN BARR VIRUS INFECTION; FEMALE; FOLLOW UP; HUMAN; LEUKEMIA RELAPSE; LYMPHOPROLIFERATIVE DISEASE; MALE; MESENCHYMAL STEM CELL; MIDDLE AGED; PILOT STUDY; PROSPECTIVE STUDY; YOUNG ADULT; ADVERSE EFFECTS; ALLOTRANSPLANTATION; ANEMIA, APLASTIC; CLINICAL TRIAL; CYTOLOGY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPSTEIN BARR VIRUS; EPSTEIN-BARR VIRUS INFECTIONS; GENETICS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LEUKEMIA; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MORTALITY; MULTICENTER STUDY; SURVIVAL RATE; VIROLOGY;

ADOLESCENT; ADULT; ANEMIA, APLASTIC; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HERPESVIRUS 4, HUMAN; HUMANS; LEUKEMIA; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 84906966129     PISSN: 09636897     EISSN: None     Source Type: Journal    
DOI: 10.3727/096368912X661319     Document Type: Article

References (42)

1. Ball, L. M.; Bernardo, M. E.; Roelofs, H.; Lankester, A.; Cometa, A.; Egeler, R. M.; Locatelli, F.; Fibbe, W. E. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stemcell transplantation. Blood 110(7):2764-2767; 2007.
2. Baron, F.; Lechanteur, C.; Willems, E.; Bruck, F.; Baudoux, E.; Seidel, L.; Vanbellinghen, J. F.; Hafraoui, K.; Lejeune, M.; Gothot, A.; Fillet G.; Beguin Y. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning. Biol. Blood Marrow Transplant. 16(6):838-847; 2010.
3. Bittencourt, H.; Rocha, V.; Filion, A.; Ionescu, I.; Herr, A. L.; Garnier, F.; Ades, L.; Esperou, H.; Devergie, A.; Ribaud, P.; Socie, G.; Gluckman, E. Granulocyte colony-stimulating factor for poor graft function after allogeneic stem cell transplantation: 3 days of G-CSF identifies longterm responders. Bone Marrow Transplant. 36(5):431-435; 2005.
4. Bolger, G. B.; Sullivan, K. M.; Storb, R.; Witherspoon, R. P.; Weiden, P. L.; Stewart, P.; Sanders, J.; Meyers, J. D.; Martin, P. J.; Doney, K. C. Second marrow infusion for poor graft function after allogeneic marrow transplantation. Bone Marrow Transplant. 1(1):21-30; 1986.
5. Bornhauser, M. A second infusion of CD34+ selected cells to improve poor graft function. Haematologica 91(7):870; 2006.
6. Chiusolo, P.; Metafuni, E.; Cattani, P.; Piccirillo, N.; Santangelo, R.; Manzara, S.; Bellesi, S.; De Michele, T.; Leone, G.; Sica, S. Prospective evaluation of Epstein-Barr virus reactivation after stem cell transplantation: Association with monoclonal gammopathy. J. Clin. Immunol. 30(6):894- 902; 2010.
7. Dominietto, A.; Raiola, A. M.; van Lint, M. T.; Lamparelli, T.; Gualandi, F.; Berisso, G.; Bregante, S.; Frassoni, F.; Casarino, L.; Verdiani, S.; Bacigalupo, A. Factors influencing haematological recovery after allogeneic haemopoietic stem cell transplants: Graft-versus-host disease, donor type, cytomegalovirus infections and cell dose. Br. J. Haematol. 112(1):219-227; 2001.
8. Doucet, C.; Ernou, I.; Zhang, Y.; Llense, J. R.; Begot, L.; Holy, X.; Lataillade, J. J. Platelet lysates promote mesenchymal stem cell expansion: A safety substitute for animal serum in cell-based therapy applications. J. Cell. Physiol. 205(2):228-236; 2005.
9. Fang, B.; Li, N.; Song, Y.; Li, J.; Zhao, R. C.; Ma, Y. Cotransplantation of haploidentical mesenchymal stem cells to enhance engraftment of hematopoietic stem cells and to reduce the risk of graft failure in two children with severe aplastic anemia. Pediatr. Transplant. 13(4):499-502.; 2009.
10. Gong, W.; Han, Z.; Zhao, H.; Wang, Y.; Wang, J.; Zhong, J.; Wang, B.; Wang, S.; Wang, Y.; Sun, L.; Han, Z. Banking human umbilical cord derived mesenchymal stromal cells for clinical use. Cell Transplant. 21(1):207-216; 2012.
11. Islam, M. S.; Anoop, P.; Gordon-Smith, E. C.; Rice, P.; Datta-Nemdharry, P.; Marsh, J. C. Epstein-Barr virus infections after allogeneic stem cell transplantation: A comparison between non-malignant and malignant hematological disorders. Hematology 15(5):344-350; 2010.
12. Karlsson, H.; Samarasinghe, S.; Ball, L. M.; Sundberg, B.; Lankester, A. C.; Dazzi, F.; Uzunel, M.; Rao, K.; Veys, P.; Le Blanc, K.; Ringdén, O.; Amrolia, P. J. Mesenchymal stem cells exert differential effects on alloantigen and virusspecific T-cell responses. Blood 112(3):532-541; 2008.
13. Karnoub, A. E.; Dash, A. B.; Vo, A. P.; Sullivan, A.; Brooks, M. W.; Bell, G. W.; Richardson, A. L.; Polyak, K.; Tubo, R.; Weinberg, R. A. Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449(7162):557-563; 2007.
14. Khakoo, A. Y.; Pati, S.; Anderson, S. A.; Reid, W.; Elshal, M. F.; Rovira, I. I.; Nguyen, A. T.; Malide, D.; Combs, C. A.; Hall, G.; Zhang, J.; Raffeld, M.; Rogers, T. B.; Stetler-Stevenson, W.; Frank, J. A.; Reitz, M.; Finkel, T. Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J. Exp. Med. 203(5):1235-1247; 2006.
15. Klingemann, H. G.; Eaves, A. C.; Barnett, M. J.; Reece, D. E.; Shepherd, J. D.; Belch, A. R.; Brandwein, J. M.; Langleben, A.; Koch, P. A.; Phillips, G. L. Recombinant GM-CSF in patients with poor graft function after bone marrow transplantation. Clin. Invest. Med. 13(2):77-81; 1990.
16. Larocca, A.; Piaggio, G.; Podesta, M.; Pitto, A.; Bruno, B.; Di Grazia, C.; Gualandi, F.; Occhini, D.; Raiola, A. M.; Dominietto, A.; Bregante, S.; Lamparelli, T.; Tedone, E.; Oneto, R.; Frassoni, F.; Van Lint, M. T.; Pogliani, E.; Bacigalupo, A. Boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation. Haematologica 91(7):935-940; 2006.
17. Le Blanc, K.; Rasmusson, I.; Gotherstrom, C.; Seidel, C.; Sundberg, B.; Sundin, M.; Rosendahl, K.; Tammik, C.; Ringden, O. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohae-magglutinin-activated lymphocytes. Scand. J. Immunol. 60(3):307-315; 2004.
18. Le Blanc, K.; Ringden, O. Mesenchymal stem cells: Properties and role in clinical bone marrow transplantation. Curr. Opin. Immunol. 18(5):586-591; 2006.
19. Le Blanc, K.; Samuelsson, H.; Gustafsson, B.; Remberger, M.; Sundberg, B.; Arvidson, J.; Ljungman, P.; Lonnies, H.; Nava, S.; Ringden, O. Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells. Leukemia 21(8):1733-1738; 2007.
20. Lee, Y. J.; Lee, S. G.; Kwon, T. W.; Park, K. M.; Kim, S. C.; Min, P. C. Risk factors for initial poor graft function and graft survival after initial poor graft function. Transplant. Proc. 28(3):1657-1658; 1996.
21. Liu, K.; Chen, Y.; Zeng, Y.; Xu, L.; Liu, D.; Chen, H.; Zhang, X.; Han, W.; Wang, Y.; Zhao, T.; Wang, J.; Wang, J.; Han, Q.; Zhao, C.; Huang, X. Coinfusion of mesenchymal stromal cells facilitates platelet recovery without increasing leukemia recurrence in haploidentical hematopoietic stem cell transplantation: A randomized, controlled clinical study. Stem Cells Dev. 20(10):1679-1685; 2011.
22. Liu, Q. F.; Fan, Z. P.; Luo, X. D.; Sun, J.; Zhang, Y.; Ding, Y. Q. Epstein-Barr virus-associated pneumonia in patients with post-transplant lymphoproliferative disease after hematopoietic stem cell transplantation. Transpl. Infect. Dis. 12(4):284-291; 2010.
23. Liu, Q. F.; Fan, Z. P.; Zhang, Y.; Jiang, Z. J.; Wang, C. Y.; Xu, D.; Sun, J.; Xiao, Y.; Tan, H. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia. Biol. Blood Marrow Transplant. 15(11):1376-1385; 2009.
24. Macmillan, M. L.; Blazar, B. R.; DeFor, T. E.; Wagner, J. E. Transplantation of ex-vivo culture-expanded parental haploidentical mesenchymal stem cells to promote engraftment in pediatric recipients of unrelated donor umbilical cord blood: Results of a phase I-II clinical trial. Bone Marrow Transplant. 43(6):447-454; 2009.
25. Maitra, B.; Szekely, E.; Gjini, K.; Laughlin, M. J.; Dennis, J.; Haynesworth, S. E.; Koc, O. N. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant. 33(6):597-604; 2004.
26. Meuleman, N.; Tondreau, T.; Ahmad, I.; Kwan, J.; Crokaert, F.; Delforge, A.; Dorval, C.; Martiat, P.; Lewalle, P.; Lagneaux, L.; Bron, D. Infusion of mesenchymal stromal cells can aid hematopoietic recovery following allogeneic hematopoietic stem cell myeloablative transplant: A pilot study. Stem Cells Dev. 18(9):1247-1252; 2009.
27. Mohty, M.; Faucher, C.; Chabannon, C.; Vey, N.; Stoppa, A. M.; Ladaique, P.; Novakovitch, G.; Olivero, S.; Bouabdallah, R.; Gastaut, J. A.; Maraninchi, D.; Blaise, D. CD34(+) immunoselected cells for poor graft function following allogeneic BMT. Cytotherapy 2(5):367-370; 2000.
28. Muller, I.; Kordowich, S.; Holzwarth, C.; Isensee, G.; Lang, P.; Neunhoeffer, F.; Dominici, M.; Greil, J.; Handgretinger, R. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplan-tation. Blood Cells Mol. Dis. 40(1):25-32; 2008.
29. Nieboer, P.; de Vries, E. G.; Vellenga, E.; van der Graaf, W. T.; Mulder, N. H.; Sluiter, W. J.; de Wolf, J. T. Factors influencing haematological recovery following high-dose chemotherapy and peripheral stem-cell transplantation for haematological malignancies; 1-year analysis. Eur. J. Cancer 40(8):1199-1207; 2004.
30. Ning, H.; Yang, F.; Jiang, M.; Hu, L.; Feng, K.; Zhang, J.; Yu, Z.; Li, B.; Xu, C.; Li, Y.; Wang, J.; Hu, J.; Lou, X.; Chen, H. The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: Outcome of a pilot clinical study. Leukemia 22(3):593-599; 2008.
31. Peralvo, J.; Bacigalupo, A.; Pittaluga, P. A.; Occhini, D.; Van Lint, M. T.; Frassoni, F.; Nardelli, E.; Transino, A.; Pantarotto, M.; Marmout, A. M. Poor graft function associated with graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplant. 2(3):279-285; 1987.
32. Potian, J. A.; Aviv, H.; Ponzio, N. M.; Harrison, J. S.; Rameshwar, P. Veto-like activity of mesenchymal stem cells: Functional discrimination between cellular responses to alloantigens and recall antigens. J. Immunol. 171(7):3426- 3434; 2003.
33. Sanchez-Guijo, F. M.; Lopez-Villar, O.; Lopez-Anglada, L.; Villaron, E. M.; Muntion, S.; Diez-Campelo, M.; PerezSimon, J. A.; San Miguel, J. F.; Caballero, D.; del Cañizo, M. C. Allogeneic mesenchymal stem cell therapy for refractory cytopenias after hematopoietic stem cell transplantation. Transfusion 52(5):1086-1091; 2012.
34. Spaeth, E. L.; Dembinski, J. L.; Sasser, A. K.; Watson, K.; Klopp, A.; Hall, B.; Andreeff, M.; Marini, F. Mesenchymal stem cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 4(4):e4992; 2009.
35. Sundin, M.; Lindblom, A.; Orvell, C.; Barrett, A. J.; Sundberg, B.; Watz, E.; Wikman, A.; Broliden, K.; Le Blanc, K. Persistence of human parvovirus B19 in multipotent mesenchymal stromal cells expressing the erythrocyte P antigen: Implications for transplantation. Biol. Blood Marrow Transplant 14(10):1172-1179; 2008.
36. Sundin, M.; Orvell, C.; Rasmusson, I.; Sundberg, B.; Ringden, O.; Le Blanc, K. Mesenchymal stem cells are susceptible to human herpesviruses, but viral DNA cannot be detected in the healthy seropositive individual. Bone Marrow Transplant. 37(11):1051-1059; 2006.
37. Suzuki, K.; Sun, R.; Origuchi, M.; Kanehira, M.; Takahata, T.; Itoh, J.; Umezawa, A.; Kijima, H.; Fukuda, S.; Saijo, Y. Mesenchymal stromal cells promote tumor growth through the enhancement of neovascularization. Mol. Med. 17(7- 8):579-587; 2011.
38. Tsukamoto, S.; Honoki, K.; Fujii, H.; Tohma, Y.; Kido, A.; Mori, T.; Tsujiuchi, T.; Tanaka, Y. Mesenchymal stem cells promote tumor engraftment and metastatic colonization in rat osteosarcoma model. Int. J. Oncol. 40(1):163-169; 2012.
39. Weng, J. Y.; Du, X.; Geng, S. X.; Peng, Y. W.; Wang, Z.; Lu, Z. S.; Wu, S. J.; Luo, C. W.; Guo, R.; Ling, W.; Deng, C. X.; Liao, P. J.; Xiang, A. P. Mesenchymal stem cell as salvage treatment for refractory chronic GVHD. Bone Marrow Transplant. 45(12):1732-1740; 2010.
40. Xuan, L.; Huang, F.; Fan, Z.; Zhou, H.; Zhang, X.; Yu, G.; Zhang, Y.; Liu, C.; Sun, J.; Liu, Q. Effects of intensified conditioning on Epstein-Barr virus and cytomegalovirus infections in allo geneichematopoietic stem cell transplantation for hematological malignancies. J. Hematol. Oncol. 5:46; 2012.
41. Zeng, W.; Kajigaya, S.; Chen, G.; Risitano, A. M.; Nunez, O.; Young, N. S. Transcript profile of CD4+ and CD8+ T cells from the bone marrow of acquired aplastic anemia patients. Exp. Hematol. 9(32):806-814; 2004.
42. Zhao, S.; Wehner, R.; Bornhauser, M.; Wassmuth, R.; Bachmann, M.; Schmitz, M. Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells Dev. 19(5):607-614; 2010.